Clinicians at Dana-Farber/Brigham and Women’s Cancer Center already use targeted therapies that pinpoint genetic mutations in a select number of cancers, including colon, lung, breast, and some leukemias and sarcomas.
The Profile program aims to identify a far greater number of mutations for a wider array of cancers, ultimately enabling clinicians to treat more cancers with targeted therapies in the future.
Related Articles on Brigham and Women’s Hospital:
Brigham and Women’s Offers Paid High School Internships to Boost Interest in Healthcare
Dr. Karen Joynt of Brigham and Women’s in Boston to Discuss Readmissions
Brigham and Women’s Hospital CIO Sue Schade: Top Health IT Priorities
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
